ARVN

Business Context and Reporting Period

Company: ARVINAS, INC. (ARVN)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Arvinas is a clinical-stage biotechnology company developing targeted protein degradation (PROTAC) therapeutics for oncology and neurology. The company has no approved products and has never generated revenue from product sales. Its primary focus is advancing a pipeline of investigational candidates, including vepdegestrant (breast cancer), ARV-102 (neurodegenerative diseases), ARV-806 (solid tumors), and ARV-393 (lymphoma).

Key Financial Metrics

Note: Revenue is derived primarily from collaboration agreements (Pfizer, Novartis) and asset sales, recognized ratably over performance periods. The company has an accumulated deficit of $1,612.4 million as of December 31, 2025.

Material Changes vs. Prior Period

• Net Loss Improvement: Net loss decreased significantly to $80.8 million in 2025 from $198.9 million in 2024. This improvement was driven by a $63.0 million decrease in R&D expenses and a $69.5 million decrease in G&A expenses, partially offset by lower interest income.
• Revenue Stability: Revenue remained relatively flat at $262.6 million, down slightly from $263.4 million. This was due to a $162.4 million decrease in revenue from the Novartis transaction (as technology transfer completed in 2024) and a $3.8 million decrease from the terminated Bayer agreement, offset by a $150.5 million increase in revenue from the Pfizer vepdegestrant collaboration due to revised cost estimates.
• Restructuring: The company implemented two workforce reductions in 2025 (33% in April and 15% in September) to streamline operations. This resulted in net restructuring charges of $3.7 million (including $15.3 million in cash severance offset by $11.6 million in non-cash reversals). Management expects annual operating cost savings of $100.0 million on a run-rate basis.
• Share Repurchases: In Q3 2025, the company authorized a $100.0 million share repurchase program. By year-end, it had repurchased approximately 10 million shares for $91.9 million and subsequently suspended the program.

Guidance, Outlook, and Risks

• Liquidity Outlook: As of December 31, 2025, the company held $685.4 million in cash and marketable securities. Management believes this is sufficient to fund operations into the second half of 2028.
• Key Catalysts:
  • Vepdegestrant: The FDA accepted the New Drug Application (NDA) for vepdegestrant (breast cancer) with a PDUFA action date of June 5, 2026. However, Arvinas and Pfizer have agreed to jointly select a third party for commercialization, meaning Arvinas will not build its own commercial infrastructure for this asset.
  • ARV-102: Phase 1 data in healthy volunteers and Parkinson's disease patients showed substantial LRRK2 degradation and a favorable safety profile. A Phase 1b trial in Progressive Supranuclear Palsy (PSP) is planned for H1 2026.
  • ARV-806: Phase 1 dose escalation for KRAS G12D solid tumors was completed ahead of plan in Q1 2026.
• Management Commentary: The company is transitioning leadership with the appointment of Randy Teel, Ph.D., as CEO in February 2026, succeeding John Houston, Ph.D. The focus remains on advancing the pipeline while maintaining cost discipline.
• Risks:
  • Commercialization Uncertainty: Reliance on a third party for vepdegestrant commercialization introduces uncertainty regarding future revenue streams and milestone payments.
  • Regulatory Risk: No products are approved; failure to obtain approval for vepdegestrant or other candidates would materially harm the business.
  • Capital Needs: The company expects to continue incurring losses and will require substantial additional funding to sustain operations beyond 2028.

Investor Verification Checklist

• Commercialization Strategy: Verify the status of the search for a third-party commercialization partner for vepdegestrant and the potential impact on future milestone payments from Pfizer.
• Cash Runway: Confirm the $685.4 million cash balance and the assumptions underpinning the "second half of 2028" liquidity projection, especially given the suspension of the share repurchase program.
• Regulatory Timeline: Monitor the June 5, 2026 PDUFA date for vepdegestrant and the potential for a Complete Response Letter (CRL) or approval.
• Restructuring Savings: Track whether the anticipated $100 million annual run-rate cost savings are realized in upcoming quarters.
• Leadership Transition: Assess the impact of the CEO transition on strategic execution and pipeline prioritization.